Effect of Modafinil on Pancreatic Exocrine Secretion in Rats. A Comparison With Adrafinil and Related Drugs

Chariot, J; Appia, F.; Vaille, C; Rozé, C

doi:10.1111/j.1472-8206.1987.tb00563.x

Cited by 4 publications

(2 citation statements)

References 7 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The peak plasma concentration of adrafinil preceded peak behavioral and EEG response by about 1 h. This finding raises the possibility that the conversion of adrafinil to modafinil, the primary metabolite, is responsible for much, if not all, of the behavioral effects of adrafinil. This suggestion is supported in the few studies that have shown that the response to adrafinil directly compares to the response to modafinil (12). However, Ferner et al (24) have found the serum levels of adrafinil to be a better predictor of its effect on EEG response than the serum levels of modafinil; the subjects with the lowest serum concentrations of adrafinil showed the least pronounced effects.…”

Section: Introductionmentioning

confidence: 92%

“…The suggestion that adrafinil does not have peripheral adrenergic effects is also supported by evidence that α 1 -adrenergic receptor agonists do not block all of the effects of adrafinil. Chariot et al (12) found that adrafinil inhibited pancreatic secretions, and this was not prevented by treatment with prazosin. In fact, this effect of adrafinil on secretion is opposite to what is normally expected of an α-adrenergic agonist.…”

Section: The a 1 -Adrenergic Receptor Hypothesismentioning

confidence: 99%

See 1 more Smart Citation

Adrafinil: A Novel Vigilance Promoting Agent

1999

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 92%

Section: The a 1 -Adrenergic Receptor Hypothesismentioning

confidence: 99%

Adrafinil: A Novel Vigilance Promoting Agent

1999

View full text Add to dashboard Cite

Toxicology of the Exocrine Pancreas

Foster¹

2009

General, Applied and Systems Toxicology

View full text Add to dashboard Cite

The exocrine pancreas is not a common target organ for toxic drugs and chemicals. It is however the fifth most common human cancer in the western world, and acute and chronic pancreatitis, through various identifiable and unidentified causes, is a common disease in both the developed and developing countries of the world. Both inflammatory disease and cancer of the pancreas is correlated to lifestyle with poor diet and habits, such as moderate to high alcohol intake and smoking, having positive correlations to developing the disease. The chapter describes the functional anatomy of the organ together with its biochemistry that determines toxicity, in particular the role of oxidant damage in the development of cell and tissue damage is thought to be important. The consequences of toxic damage to the acinar cells are severe and primarily result from the auto‐activation and hence autodigestion of the tissue by the digestive enzymes normally contained within the exocrine cells, a cascade of apoptosis/necrosis and fibrosis with the ultimate collapse of the organ, subsequent shock, multi‐organ collapse and death. The organ has complex molecular mechanisms to prevent premature activation of the digestive enzymes and also has defence mechanisms present to neutralise any premature enzyme activation but these can be rendered ineffectual by factors such as alcohol abuse and a poor diet. Chemical exposure, through both occupational and consumer product usage, has been associated with the development of both pancreatic neoplastic and non‐neoplastic disease but the relationship between exposure and disease has never developed further than a simple association and it is likely that the development of pancreatic disease is a multi‐faceted combination of inter‐related events, none of which in isolation can induce disease. The pancreas has its own array of phase 1 and 2 metabolic enzyme systems and the role of pancreatic drug and chemical activation and detoxification in inducing toxicity is discussed together with the possible secondary effects of hepatic drug/chemical activation and detoxification. Finally the role of animal models of pancreatic disease is discussed in terms of their contribution to understanding the aetiology of the human conditions and the possible use of therapeutic intervention in treating the disease.

show abstract